Neoadjuvant therapy for oesophageal cancer: refining the armamentarium
Mené au Japon sur 601 patients atteints d'un carcinome épidermoïde de l'oesophage de stade localement avancé (âge : 20-75 ans ; durée médiane de suivi : 50,7 mois), cet essai randomisé multicentrique de phase III compare l'efficacité, du point de vue de la survie globale, et la sécurité d'un traitement par doublet de chimiothérapie néoadjuvante (fluorouracile-cisplatine), par triplet de chimiothérapie néoadjuvante (fluorouracile-cisplatine-docétaxel) ou par un doublet de chimiothérapie (fluorouracile-cisplatine) associé à une radiothérapie
Oesophageal squamous cell cancer (OSCC) has a poor prognosis, with a 5-year overall survival rate of 20–25% even in localised stages.1 The global standard for treating resectable OSCC is multimodal therapy, typically involving neoadjuvant chemotherapy or chemoradiation, followed by surgery. This approach has proven to be more effective than surgery alone.2–4 However, the best chemotherapy or chemoradiation regimen remains a topic of debate, with considerable regional differences in treatment protocols. Patients with OSCC represent a challenging group to treat due to their substantial comorbidities, which are often linked to the primary risk factors for OSCC (such as cigarette smoking and alcohol consumption) and complicate and limit treatment options.